CGRP Antibodies: A New Era in Migraine Prevention in Austria
- MigraineMind
- Dec 5, 2025
- 1 min read
Research Summary
A recent study published in the European Journal of Neurology explored the use of monoclonal antibodies against calcitonin gene-related peptide (CGRP-mAbs) for migraine prevention in Austria. Analyzing nationwide insurance data over 49 months, researchers found that out of 8.8 million people, 8,934 were prescribed CGRP-mAbs, with a median treatment duration of 297 days. The study highlighted that 43% of patients used CGRP-mAbs for at least one year, though 63% experienced therapy breaks. Notably, 54% resumed the same CGRP-mAb within a year of stopping. The research underscored excellent persistence with CGRP-mAbs and a decrease in triptan use, indicating potential long-term benefits.
Study Details
👥 Research Team: Zebenholzer K et al.
📚 Published In: Eur J Neurol
📅 Publication Date: 2025 Dec
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.